Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma

Zhenhua Qi¹,¹, Fang Yan¹,¹, Dongtai Chen¹, Wei Xing¹, Qiang Li¹, Weian Zeng¹, Bingtian Bi²,* Jingdun Xie¹,*

¹Department of Anesthesiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation for Cancer Medicine, Guangzhou, Guangdong 510060, China

²Department of Clinical Trial Center, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation for Cancer Medicine, Guangzhou, Guangdong 510060, China

*Corresponding Authors: Jingdun Xie and Bingtian Bi

E-mail addresses: xiejd6@mail.sysu.edu.cn;

bibt@sysucc.org.cn;

# Zhenhua Qi and Fang Yan contributed equally to this work.
Abstract

The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway induces innate immunity by activating the production of inflammatory cytokines and type I interferons. Recently, studies revealed that self-DNA from by-products of chromosome instability and tumors could activate the cGAS-STING pathway, and subsequently promote or inhibit tumor development. However, the prognostic value and correlations with immune infiltrates of the cGAS-STING pathway in hepatocellular carcinoma (HCC) have not been clarified. In this study, we used the Molecular Signatures Database, Oncomine, UALCAN, Human Protein Atlas, Kaplan–Meier plotter, LinkedOmics, and Tumor Immune Estimation Resource databases. Overexpression of XRCC5, IRF3, TRIM21, STAT6, DDX41, TBK1, XRCC6, TREX1, PRKDC, and TMEM173 was markedly correlated with clinical stages and pathological grades in HCC. Moreover, higher mRNA expression of XRCC5, XRCC6, and PRKDC was significantly related with shorter overall survival. However, higher mRNA expression of IFI16, STAT6, NLRC3, and TMEM173 was associated with favorable overall survival. Our results suggested that the kinase targets of the cGAS-STING pathway included the SRC family of tyrosine kinases (LCK and LYN), phosphoinositide 3-kinase-related protein kinase (PIKK) family kinases (ATM and ATR), and mitogen-activated protein kinase 1 (MAPK1). Furthermore, we identified significant correlations among the expression of cGAS-STING pathway and infiltration of B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells in HCC. The expression of the cGAS-STING pathway also exhibited strong relationships with diverse immune marker sets in HCC. These
findings suggest that cGAS-STING pathway members may be used as prognostic biomarkers and immunotherapeutic targets HCC patients.

**Keywords**

cGAS-STING; hepatocellular carcinoma; tumor-infiltrating; prognosis

**Introduction**

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide (1). The 5-year survival rate of patients with advanced liver cancer is poor due to high tumor recurrence, metastasis, and the lack of early diagnostic biomarkers with high sensitivity and specificity (2). Owing to poor liver function correlated with cirrhosis and extrahepatic metastasis, most patients with HCC are resistant to common cytotoxic therapies (3). Although doxorubicin was initially viewed as a first-choice drug for advanced HCC, a controlled trial showed that it was related with a low survival rate (4). The overall life expectancy of patients with advanced HCC does not exceed 1 year even under treatment with sorafenib or regorafenib (5). Therefore, there is an urgent need to identify novel potential prognostic and therapeutic targets that are related with tumor formation and progression in patients with HCC.

Cyclic GMP-AMP synthase (cGAS) is activated to catalyze the synthesis of cyclic GMP-AMP (cGAMP) on binding to DNA. Moreover, cGAMP acts as a second messenger, which binds to and induces the stimulator of interferon genes (STING) (6, 7). The palmitoylation of STING mediates the recruitment and activation of TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3) to produce cytokines, such as type I interferons (IFNs) (8, 9). STING also acts...
downstream of several other cytosolic DNA sensors, including DEAD-box helicase 41 (DDX41) and interferon gamma inducible protein 16 (IFI16) in the signaling pathway to produce type I IFNs. Knockdown of DDX41 expression inhibited the ability of myeloid dendritic cells (DCs) to mount cytokine and type I IFN responses to DNA, as well as DNA viruses. Lowering the expression of IFI16 by RNA-mediated interference blocked gene induction and activation of IRF3 (10, 11). The cGAS-STING pathway is an important DNA-sensing machinery in innate immunity and viral defense, and critically involved in tumor development (12, 13). Conditional deletion of TBK1 in lung epithelial cells could inhibit tumorigenesis of lung cancer in a mouse model. Besides promoting tumor growth, TBK1 was also involved in tumor-mediated immunosuppression (14). Signal transducer and activator of transcription 6 (STAT6) is overexpressed in various human cancers, and is a regulator involved in multiple biological processes of cancers. Studies demonstrated that STAT6 silencing could induce apoptosis and growth inhibition in HCC-derived cells (15).

Recently, studies revealed that the prognosis of patients with tumors was correlated with the expression of cGAS-STING pathway members (16, 17). Cancer immunotherapy is an effective treatment against a number of cancers. Thomsen suggested that modulation of the cGAS-STING pathway could affect the tumor progression of HCC, and potentially be used as a treatment in patients with HCC (18). Through overexpression and RNA interference, Wang et al. demonstrated that cGAS responded to exogenous dsDNA from the DNA damage response, and subsequently triggered the activation of STING/TBK1-mediated innate immunity in chicken liver cancer (19). XRCC5 variants play a crucial role in determining susceptibility to
HCC (20). A previous study found that aberrant splicing of IRF3 could result in defects in IFN-mediated antiviral defenses in HCC (21). Research demonstrated that DNA damage repair by XRCC6 could reverse TLR4-deficiency-worsened liver cancer development by recovering immunity to support autophagy and senescence (22). An in vivo study showed that restored expression of IFI16 could effectively promote tumor regression, which could be partly abrogated by inhibition of the induced inflammasome in HCC (23). These findings suggest that cGAS-STING pathway members are potential prognostic biomarkers and therapeutic targets and may be associated with immune infiltration in patients with HCC. However, the identification of suitable cGAS-STING pathway members for this purpose remains an important problem that requires urgent attention.

In our study, we searched for cGAS-STING pathway genes present in both the Molecular Signatures Database (MSigDB) and Oncomine database, and in relevant literature (7, 13). We selected 13 key genes of the cGAS-STING pathway members, namely XRCC5, IRF3, TRIM21, IFI16, STAT6, NLRC3, DDX41, TBK1, XRCC6, TREX1, PRKDC, cGAS, and STING (also termed TMEM173). The genes regulated by the cGAS and STING signaling axis include TBK1, IRF3, and STAT6. Moreover, the genes which regulate the pathway include TREX1, DDX41, IFI16, and NLRC3. These signature genes of the cGAS-STING pathway are linked to type I IFN response. Firstly, we compared the expression of cGAS-STING pathway members in HCC tissues and normal tissues via Oncomine, UALCAN, and the Human Protein Atlas. We subsequently analyzed the correlations between these key genes and prognosis in patients with liver cancer using the Kaplan–Meier (K–M) plotter. In addition, we also investigated potential kinase targets of the cGAS-STING pathway members in
patients with HCC using LinkedOmics. To further investigate potential immune therapeutic targets, we analyzed the correlations among the expression of cGAS-STING pathway members and immune cell infiltration and diverse immune marker sets in HCC microenvironments obtained from the Tumor Immune Estimation Resource (TIMER) database.

Materials and Methods

MSigDB analysis

The comprehensive database MSigDB (www.gsea-msigdb.org/gsea/msigdb/) includes >10,000 gene sets and is widely used to perform gene set enrichment analysis (24). In the present study, we searched this database to obtain cGAS-STING pathway genes.

Oncomine database analysis

Oncomine (www.oncomine.org) is a cancer microarray database, including 715 datasets and 86,733 samples for DNA or RNA sequence analysis (25). Oncomine can be used to analyze differences in gene expression between tumor tissues and normal tissues. In this study, we noted the transcriptional expression of cGAS-STING pathway genes between 20 different cancer samples and their normal adjacent tissues from the Oncomine database. The threshold was determined based on the following values: p=0.01, fold change=1.5, gene rank=10%, and data type for mRNA.

UALCAN database analysis

UALCAN (http://ualcan.path.uab.edu) is an interactive web server for the analysis of 31 types of cancer with transcriptome data from The
Cancer Genome Atlas (TCGA). This tool is based on clinical data and level 3 RNA-sequence. UALCAN can be used to assess the association of transcriptional expression with relative clinicopathologic features (26). In our study, UALCAN was utilized to analyze the mRNA expression of cGAS-STING pathway genes in HCC tissues, and estimate their association with clinicopathologic features. A p<0.05 denoted statistically significant difference.

**Human Protein Atlas**

The Human Protein Atlas (https://www.proteinatlas.org) is an online site containing immunohistochemistry-based expression data for approximately 20 common types of tumors. It is used to map the human proteins in organs, tissues, and cells through integration of different omics technologies, such as mass spectrometry-based proteomics and transcriptomics (27). In the present study, the protein expression of different cGAS-STING pathway genes between human normal and HCC tissues was compared using immunohistochemistry images.

**K–M plotter database analysis**

The K–M plotter (www.kmplot.com) is used to estimate the effect of 54,000 genes for prognostic analysis in 21 common types of cancer. The database contains gene chip and RNA-sequence data-sources obtained from databases, such as the Gene Expression Omnibus (28, 29). We evaluated the prognostic value of the mRNA expression of cGAS-STING pathway genes in liver cancer via the K–M plotter database. We divided patients according to the median and accepted other default settings prior to the analysis. The hazard ratio (HR) with 95% confidence intervals and log-rank p-values was computed. A
p<0.05 denoted statistically significant differences.

**LinkedOmics**

LinkedOmics (http://www.linkedomics.org/) is a publicly available portal containing all 32 types of cancer included in TCGA. It serves as a unique tool for biologists and clinicians to access, compare, and analyze cancer multi-omics data (30). In this study, we determined the kinase target enrichment of cGAS-STING pathway genes using the “LinkInterpreter” module. We conducted analyses with a number of size of 3 and simulations of 500 in LIHC dataset. We considered 0.05 as the p-value cutoff and used the Spearman correlation test to analyze the results statistically.

**TIMER database analysis**

TIMER (https://cistrome.shinyapps.io/timer/) is a reliable database for estimating immune cell infiltration using data from TCGA, including 10,897 samples from 32 types of cancer (31). In this study, we initially analyzed the expression of cGAS-STING pathway genes in HCC. Subsequently, we examined the correlation between the expression of cGAS-STING pathway members and immune cell infiltrates, including B cells, CD8+ T cells, CD4+ T cells, macrophages, DCs, and neutrophils with gene modules. Highly expressed genes in the tumor microenvironment tend to have negative correlations with tumor purity (32). The generated scatterplots suggest statistical significance and provide the purity-corrected partial Spearman’s rho value. Further, correlations between the expression of cGAS-STING pathway members and gene markers of immune cells were further evaluated with correlation modules. The cGAS-STING pathway genes were represented on the
x-axis, and related marker genes were used for the y-axis. Options for partial correlation under the condition of tumor purity were conducted.

**Statistical analysis**

The results generated from Oncomine were displayed with fold changes, p-values, and t-test results. Survival curves were generated via K–M plots. The results of KM plots were presented by p-values and HR obtained from a log-rank test. A p<0.05 denoted statistically significant differences.

**Results**

**mRNA expression levels of cGAS-STING pathway members in HCC**

We analyzed the differences in the transcriptional levels of cGAS-STING pathway members in patients with HCC using the Oncomine database. The results revealed that the mRNA expression of TRIM21, IFI16, NLRC3, DDX41, XRCC6, TREX1, PRKDC, and TMEM173 was significantly higher in HCC tissues in multiple datasets (Figure 1 and Table 1). In the Wurmbach Liver dataset (33), higher expression of TRIM21 was revealed in HCC tissues compared with normal adjacent tissues (fold change=1.607 and p=4.78E-04).

Upregulation of IFI16 was also found in HCC tissues compared with normal adjacent tissues. The data from the Mas Liver dataset (34) showed increase of 3.474-fold (p=4.23E-14) and 4.715-fold (p=1.91E-16), respectively. Wurmbach (33) observed a 3.649-fold (p=1.02E-06) and 2.250-fold (p=4.06E-04) increase, respectively, in IFI16 mRNA expression in HCC samples. Wurmbach (33) also found a 2.197-fold (p=1.35E-05) increase in NLRC3 mRNA expression in HCC tissues. Similarly, in the Roessler Liver dataset (35), 2.012-fold
(p=7.60E-8) and 1.701-fold (p=2.95E-41) increases in DDX41 mRNA expression were found in HCC samples compared with normal tissues. Wurmbach (33) observed a 1.719-fold (p=5.25E-7) increase in DDX41 mRNA expression in HCC samples. In the Roessler Liver 2 dataset (35), high expression of XRCC6 was observed in liver cancer tissues compared with normal adjacent tissues (fold change =1.828 and p=1.47E-70, respectively). In addition, TREX1 showed higher expression levels in HCC tissues versus normal tissues in Wurmbach Liver (fold change=1.552 and p=0.002) (33). Similarly, results from three datasets suggested that PRKDC expression was higher in HCC tissue versus normal adjacent tissue (33, 35, 36). The mRNA expression of cGAS was not found on Oncomine.

We also investigated the mRNA expression levels of cGAS-STING pathway members in HCC tissue with UALCAN. As shown in Figure 2, the transcriptional levels of XRCC5, IRF3, TRIM21, STAT6, DDX41, TBK1, XRCC6, TREX1, PRKDC (all p<0.001) and TMEM173 (p<0.05) in HCC tissues were significantly upregulated (Figures 2 A–C, E, G–L). However, the transcriptional levels of IFI16 (p=7.04E-02) and NLRC3 (p=9.95E-02) did not show significant differences (Figures 2D, F). The mRNA expression of cGAS was not found on UALCAN.

After confirming the upregulation of mRNA expression levels of cGAS-STING pathway members in HCC tissues, we subsequently assessed their protein expression levels based on the Human Protein Atlas website. As shown in Figure 3, STAT6, TBK1, and TREX1 proteins were not expressed in normal liver tissues, whereas they exhibited medium or high expressions in HCC samples (Figures 3D, F, H). In addition, low or medium protein expression of XRCC5, IRF3, TRIM21, DDX41, XRCC6, and cGAS was observed in normal liver
tissues, while high protein expression was detected in HCC tissues (Figures 3A–C, E, G, I). However, the immunohistochemical images of IFI16, NLRC3, PRKDC, and TMEM173 expression were not found in this website. In general, these results revealed that the transcription and protein levels of most cGAS-STING pathway members were upregulated in patients with HCC.

We next analyzed the correlation between the mRNA expression of cGAS-STING pathway members and the pathological stage of patients with liver cancer according to UALCAN. The results are presented in Figures 4 and 5. The mRNA expression of cGAS-STING pathway members, except for IFI16 and NLRC3, was significantly related with individual cancer stages and tumor grades in HCC. Furthermore, patients in advanced stages and tumor grades of HCC had higher mRNA expression levels of cGAS-STING pathway members compared with those in early stages of the disease. In Figure 4, the highest mRNA expression of DDX41 was found in stage 4 (Figure 4G), while the highest mRNA expression of XRCC5, IRF3, TRIM21, STAT6, TBK1, XRCC6, TREX1, and PRKDC was found in stage 3 (Figures 4A–C, E, H–K), which may be attributed to the small sample numbers (only six patients with stage 4 HCC). Figure 4L shows that the highest mRNA expression of TMEM173 was found in stage 1. Similarly, the highest mRNA expression of XRCC5, IRF3, DDX41, TBK1, XRCC6, and PRKDC was found in grade 4 tumors (Figures 5A, B, G–I, K), while the highest mRNA expression of TRIM21, STAT6, and TMEM173 was found in grade 3 (Figures 5C, E, L). However, the highest mRNA expression of IFI16 and TREX1 was found in grade 1 or 2; as the tumor grade increased, their mRNA expression tended to be lower (Figures 5D, J). These results suggested that XRCC5, IRF3, TRIM21, STAT6, DDX41, TBK1, XRCC6, TREX1, PRKDC, and
TMEM173 were strongly correlated with tumorigenesis and tumor progression in patients with HCC.

**Prognostic value of mRNA expression of cGAS-STING pathway members among patients with HCC**

We further analyzed the prognostic potential of mRNA expression of cGAS-STING pathway members in patients with HCC using the K–M plotter. Overall survival (OS) curves are illustrated in Figure 6. Higher mRNA expression of XRCC5 (HR: 1.74, 95% confidence interval [CI]: 1.22–2.48, p=0.0018), XRCC6 (HR: 1.63, 95% CI: 1.15–2.31, p=0.0056), and PRKDC (HR: 1.89, 95% CI: 1.24–2.88, p=0.0025) were related with shorter OS (Figures 6A, I, K). In contrast, higher mRNA expression of IFI16 (HR: 0.68, 95% CI: 0.48–0.97, p=0.032), STAT6 (HR: 0.57, 95% CI: 0.4–0.81, p=0.0016), NLRC3 (HR: 0.45, 95% CI: 0.32–0.65, p=7.5e-06), and TMEM173 (HR: 0.59, 95% CI: 0.41–0.85, p=0.0036) was correlated with favorable OS (Figures 6D–F, L). However, the mRNA expression of IRF3 (p=0.34), TRIM21 (p=0.07), DDX41 (p=0.14), TBK1 (p=0.051), and TREX1 (p=0.14) did not show a correlation with prognosis in patients with HCC (Figures 6B, C, G, H, J). These results suggested that the mRNA expression of XRCC5, XRCC6, PRKDC, IFI16, STAT6, NLRC3, and TMEM173 was associated with the prognosis of patients with HCC. The prognostic data of cGAS were not found in the K–M plotter.

**Kinase targets of cGAS-STING pathway members in HCC**

Based on the significantly different expression of cGAS-STING pathway members in HCC tissues versus normal tissues, we estimated possible kinase targets of the differentially expressed cGAS-STING pathway members. In this study, we investigated the
top two kinase targets of cGAS-STING pathway members via the LinkedOmics database. As shown in Table 2, PLK1 and ATR were the top two kinase targets of XRCC5. DYRK1A and EGFR were noted as the targets for the IRF3 kinase-target network. LYN and LCK were mainly correlated with TRIM21. Constituents of the IFI16 kinase-target network were primarily correlated with SYK and LCK.

ATR and PLK1, and LCK and SYK were the top two kinase targets of STAT6 and NLRC3, respectively. Mitogen-activated protein kinase 1 (MAPK1) and DYRK1A were regarded as the kinase targets of DDX41. ATM and DAPK1 were mainly related with TBK1. AURKB and PLK1 were shown as kinase targets of XRCC6. ATM and CDK2, as well as ATM and CDK1, were the top two targets of TREX1 and PRKDC, respectively. BUB1 and HCK were regarded as the kinase targets of TMEM173. The kinase targets of cGAS were not found in the LinkedOmics database.

**Immune cell infiltration of cGAS-STING pathway members in HCC**

Tumor-infiltrating lymphocytes can be used as independent predictors for sentinel lymph node status and survival in cancer (37). Therefore, we investigated the correlations between differentially expressed cGAS-STING pathway members and the infiltration of immune cells using the TIMER database. As shown in Figure 7, there was a positive relationship between the expression of XRCC5, IRF3, TRIM21, IFI16, NLRC3, DDX41, TBK1, XRCC6, and PRKDC, and the infiltration of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and DCs (Figures 7A–D, F–I, K). STAT6 expression (Figure 7E) was positively associated with the infiltration of CD8+ T cells (correlation: 0.173, p=1.28e−03), macrophages (correlation: 0.218, p=4.87e−05), neutrophils (correlation: 0.287, p=5.47e−08).
CD4+ T cells (correlation: 0.277, p=1.83e−07), and DCs (correlation: 0.213, p=7.61e−05). Similarly, the expression of TREX1 (Figure 7J) was correlated with the infiltration of CD8+ T cells (correlation: 0.121, p=2.48e−02), and neutrophils (correlation: 0.218, p=4.36e−05). These results strongly suggested that, in patients with liver cancer, the cGAS-STING pathway may act a specific role for immune cell infiltration, including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DCs.

**Correlation analysis between the expression of the cGAS-STING pathway and immune marker sets**

We investigated the relationships between cGAS-STING pathway members and different marker genes of immune cells of HCC using the TIMER database. The immune marker sets of various immune cells, such as monocytes, M1 and M2 macrophages, tumor-associated macrophages (TAMs), and DCs were analyzed. In addition, we investigated various functional T cells, such as T helper 1 (Th1), Th2, and regulatory T (Treg) cells. The results are presented in Supplementary Tables 1–3. After correlation adjustment by purity, we found that the expression levels of cGAS-STING pathway members were significantly related with most immune marker sets of different immune cells and various functional T cells in liver cancer.

Importantly, the expression of immune marker sets of TAMs, monocytes, M1 and M2 macrophages was associated with the expression levels of most cGAS-STING pathway members, including XRCC5, TRIM21, IFI16, STAT6, NLRC3, TBK1, XRCC6, and PRKDC (Supplementary Tables 1–3).

Furthermore, the results also suggested that the expression of most marker sets of DCs, such as HLA-DPB1, CD1C, NRP1, and
ITGAX had strong correlations with XRCC5, TRIM21, IFI16, STAT6, NLRC3, TBK1, XRCC6, and PRKDC expression in HCC (Supplementary Tables 1–3). These results suggested that there was a strong correlation between cGAS-STING pathway members and DC infiltration. In addition, there was a significant connection between FOXP3 and TGFβ1 for Treg cells and cGAS-STING pathway members in HCC.

Significant correlations between cGAS-STING pathway members, (e.g., XRCC5, TRIM21, IFI16, STAT6, NLRC3, TBK1, XRCC6, and PRKDC) and marker gene sets of Treg and T cell exhaustion (e.g., FOXP3, STAT5B, CCR8, PDCD1, TGFβ1, LAG3, CTLA4, and HAVCR2) are also presented in Supplementary Tables 1–3. The cGAS-STING pathway members exhibited significant correlations with immune infiltrating cells in HCC, and may play an important role in immune escape in the liver cancer microenvironment.

**Discussion**

The cGAS–STING pathway has emerged as a potential mechanism to induce inflammation-mediated tumorigenesis. Actually, persistent activation of this pathway and its downstream effectors, such as TBK1, has been connected with chronic inflammation and cancer progression (38, 39). The development of HCC is a multistep process that involves continuous inflammatory damage, such as hepatocyte necrosis (40). Some studies have observed correlations between cGAS–STING pathway members, the tumor microenvironment, and cancer immunotherapy. However, the prognostic value and potential therapeutic targets of the cGAS–STING pathway in HCC are poorly characterized. In this study, we investigated the expression, prognostic values, and correlations with immune infiltrates of
different cGAS-STATING pathway members in HCC.

We first investigated the expression of cGAS-STATING pathway members and its correlations with the pathological stage in HCC. Based on the Oncomine database, the mRNA expression of TRIM21, IFI16, NLRC3, DDX41, XRCC6, TREX1, PRKDC, and TMEM173 was significantly higher in HCC tissues in multiple datasets. Moreover, in patients with HCC, high expression of mRNA and protein was found in cGAS-STATING pathway member genes, including XRCC5, IRF3, TRIM21, STAT6, DDX41, TBK1, XRCC6, TREX1, PRKDC, and TMEM173. Furthermore, the mRNA expression of these 10 genes was strongly associated with cancer stages and tumor grades in patients with HCC. These data demonstrate that differentially expressed cGAS-STATING pathway members may play a significant role in HCC. Recently, high expression of XRCC5 has been found in breast and gastric cancer (17, 41). A strong correlation was found between the variable number tandem repeat polymorphism in the XRCC5 gene and the risk of breast cancer (17). Overexpression of XRCC5 was also detected in gastric cancer, in which XRCC5 regulated the overexpression of chloride channel 3 (CLC3) (41). Additionally, Liu (42) found that higher expression of XRCC5 was related with metastasis through the Wnt/β-catenin signaling pathway in patients with HCC, which was consistent with our results. In conclusion, XRCC5 may participate in the tumorigenesis of HCC.

Recently, Shi found that pharmacological targeting or knockdown of IRF3 using amlexanox. This drug is used for anti-inflammatory treatment, and can inhibit gastric tumor growth in a Yes-associated protein-dependent manner. The expression of IRF3 is upregulated and prognosticates patient survival in gastric cancer (43). A study showed that the expression of TBK1 was increased in mesenchymal
small cell lung cancer cell lines (44). Research found that TRIM21 modulated epithelial–mesenchymal transition (EMT) by regulating the stability of Snail in breast cancer (45). To our knowledge, this was the first study to investigate the correlation among IRF3, TBK1, and TRIM21 with HCC. Our results suggested that all three may participate in the tumorigenesis of HCC.

The potential prognostic value of the mRNA expression levels of cGAS-STING pathway members in patients with HCC was subsequently investigated. The findings revealed that higher mRNA expression of XRCC5, XRCC6, and PRKDC was significantly associated with shorter OS. In contrast, higher mRNA expression of IFI16, STAT6, and NLRC3 was significantly related with better OS. Liu (42) observed that the high mRNA expression of XRCC5 predicted poor prognosis in patients with HCC, which was in accordance with our results. Studies have shown that NLRC3 was a negative regulator in innate immune signaling activated by STING. NLRC3 could inhibit STING-TBK1 interaction and the production of downstream type I IFN (46). IFI16 enhanced STING activation by interacting with STING via the PYRIN domain. Moreover, the IFI16-induced inflammasome was found to inhibit HCC growth and metastasis, and was a tumor suppressor during the development (23). In our study, we found that NLRC3 and IFI16 were independent prognostic factors for favorable OS in patients with liver cancer.

We also investigated the kinase targets of the cGAS-STING pathway members. We discovered that the SRC family of tyrosine kinases (LCK and LYN), phosphoinositide 3-kinase-related protein kinase (PIKK) family kinases (ATM and ATR), and MAPK1 were potential kinase targets of the cGAS-STING pathway members. These kinase targets affect the progression of cell cycle, DNA
damage, and EMT (47-51). Furthermore, they are involved in tumor progression by mediating tumor cell invasion, apoptosis, and migration (51-53). As a result, differentially expressed cGAS-STING pathway members may modulate DNA repair, the EMT, and cell cycle progression by regulating these kinases in patients with HCC.

Another important finding in this study is that the expression of cGAS-STING pathway members is associated with various immune cell infiltration levels in liver cancer. The cGAS-STING pathway can mediate protective immune defense toward infection with a great number of DNA-containing pathogens, as well as generate intrinsic antitumor immunity (54). The accumulation of tumor DNA could activate STING-IRF3-induced IFN signaling to enforce tumor-antigen presentation on DCs and cross-prime CD8⁺ T cells for antitumor immunity (55). There is an increasing body of evidence supporting that immune cell infiltration could affect cancer recurrence and progression, and also play an important role in clinical outcome and response to immunotherapy (56, 57). CD4⁺ T cells may be involved in the recognition of tumor antigens, and the activation of M1 macrophages may mediate the inhibition of tumor growth (58). Our results demonstrate that there is a significant correlation between the expression of cGAS-STING pathway members and the infiltration of immune cells, such as T cells, macrophages, and DCs. This implies that cGAS-STING pathway members may act as potential prognostic indicators, as well as reflect the immune status. STING activation in hepatic macrophages could induce the production of proinflammatory cytokines, leading to nonalcoholic steatohepatitis that is characterized by hepatic steatosis (59).

Moreover, the correlations between the expression of cGAS-STING pathway members and the marker sets of immune cells
suggest the role of cGAS-STING pathway members in regulating
tumor immunology in HCC. Firstly, the M1 macrophage markers (e.g.,
IRF5 and PTGS2) and the marker genes of M2 macrophages (e.g.,
VSIG4, and MS4A4A) were significantly associated with the
expression of XRCC5, TRIM21, IFI16, STAT6, NLRC3, TBK1, XRCC6,
and PRKDC. Collectively, the results suggest the regulatory role of
these cGAS-STING pathway genes in the polarization of TAMs.
Moreover, our results reveal a strong relationship between the
expression of XRCC5, TRIM21, IFI16, STAT6, NLRC3, TBK1, XRCC6,
and PRKDC and DC infiltration. These genes also play a potential
role in activating Treg cells and inducing T cell exhaustion. DCs
promote tumor metastasis by reducing the cytotoxicity of CD8+ T cells
and increasing Treg cells (60). Further studies are warranted to
investigate whether these genes are important factors in inducing the
DCs and tumor metastasis.

In addition, the increase in the expression of XRCC5, TRIM21,
IFI16, STAT6, NLRC3, TBK1, XRCC6, and PRKDC was significantly
related with the expression of Treg and T cell exhaustion gene
markers, such as FOXP3, STAT5B, TGFβ1, PDCD1, CTLA4, HAVCR2,
and LAG3 in patients with HCC. HAVCR2 is an important surface
protein from exhausted T cells (61). In human squamous cell
carcinomas, STING signaling abrogated tumor immunogenicity by
recruiting Treg cells (62). This is highly correlated with the
expression of XRCC5, TRIM21, IFI16, STAT6, NLRC3, TBK1, XRCC6,
and PRKDC in HCC. Furthermore, significant associations were also
found between the expression of XRCC5, TRIM21, IFI16, STAT6,
NLRC3, TBK1, XRCC6, and PRKDC and the regulation of some
marker genes of T helper cells (e.g., Th1, Th2, and Th17). These
associations suggest the potential mechanism through which these
cGAS-STING pathway members may regulate T cell functions in HCC. Collectively, the results suggest that cGAS-STING pathway members (e.g., XRCC5, TRIM21, IFI16, STAT6, NLRC3, TBK1, XRCC6, and PRKDC) may play a crucial role in the regulation and recruitment of immune infiltrating cells in HCC.

This study had some limitations. Firstly, all the data in this study were obtained from online databases; hence, further studies involving larger sample sizes, and in vitro and in vivo experiments are warranted to confirm our results. Secondly, analysis based on the transcriptional levels may indicate a few aspects of the immune status however, its ability to detect global changes is limited. Finally, we did not analyze the potential mechanisms of cGAS-STING pathway members in HCC. Future studies should be performed to investigate the detailed mechanism among cGAS-STING pathway members and HCC.

Conclusions

XRCC5, IRF3, TRIM21, STAT6, DDX41, TBK1, XRCC6, TREX1, PRKDC, and TMEM173 were found to be significantly positive correlated with clinical cancer stages and tumor grades in patients with liver cancer. In addition, high mRNA expression of XRCC5, XRCC6, and PRKDC was significantly related with poor OS. In contrast, high mRNA expression of IFI16, STAT6, NLRC3, and TMEM173 was strongly correlated with favorable OS in HCC. Increased expression levels of cGAS-STING pathway members are correlated with increased infiltration levels of immune cells, including B cells, CD8+ T cells, CD4+ T cells, neutrophils, macrophages, and DCs in HCC. Therefore, cGAS-STING pathway members, especially XRCC5, IFI16, STAT6, NLRC3, XRCC6, and PRKDC, are likely
involved in immune infiltration and can be used as potential prognostic biomarkers for patients with HCC. We hope our results provide a new perspective for the design of new immunotherapeutic drugs against HCC.

Data Accessibility

The data that support the findings of our study are openly available from Molecular Signatures Database (MSigDB), Oncomine database, UALCAN, Human Protein Atlas, Kaplan–Meier plotter, LinkedOmics, and Tumor Immune Estimation Resource (TIMER) database (https://www.gsea-msigdb.org/gsea/msigdb/, www.oncomine.org, http://ualcan.path.uab.edu, https://www.proteinatlas.org, www.kmplot.com, http://www.linkedomics.org/, https://cistrome.shinyapps.io/timer/).

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the National Key Research and Development Program of China (Grant No. 2018YFC2001901), National Natural Science Foundation of China (Grant No. 81701074), and Research Foundation of Guangdong Medical Science and Technology (Grant No. A2018236).

Author Contributions

Zhenhua Qi designed the project. Zhenhua Qi and Fang Yan wrote the original manuscript and conducted the formal analysis. Dongtai
Chen and Wei Xing contributed to the bioinformatics analysis. Qiang Li and Weian Zeng reviewed the manuscript. Bingtian Bi and Jingdun Xie contributed to data curation and acquisition of funding.

Abbreviations

cGAMP, cyclic GMP-AMP; cGAS, cyclic GMP-AMP synthase; DC, dendritic cells; DDX41, DEAD-box helicase 41; HCC, hepatocellular carcinoma; IFI16, interferon gamma inducible protein 16; IRF3, interferon regulatory factor 3; MAPK1, mitogen-activated protein kinase 1; PIKK, phosphoinositide 3-kinase-related protein kinase; STAT6, signal transducer and activator of transcription-6; STING, stimulator of interferon response cGAMP interactor; TBK1, TANK-binding kinase 1; TMEM173, transmembrane protein 173.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 2015;64(5):842-8.
3. Assenat E, Pageaux G-P, Thézenas S, Peron J-M, Bécouarn Y, Seitz J-F, et al. Sorafenib alone vs. sorafenib plus GEMOX as 1-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer. 2019;120(9):896-902.
4. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25(21):3069-75.
5. Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66.
6. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339(6121):826-30.
7. Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet. 2019;20(11):657-74.
8. Zhao B, Du F, Xu P, Shu C, Sankaran B, Bell SL, et al. A conserved PLPLRT/SD motif of STING mediates the recruitment and activation of TBK1. Nature. 2019;569(7805):718-22.
9. Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, et al. Phosphorylation of innate immune adaptor
proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 2015;347(6227):aaa2630.
10. Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu Y-J. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol. 2011;12(10):959-65.
11. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010;11(11).
12. Zheng Z, Jia S, Shao C, Shi Y. Irradiation induces cancer lung metastasis through activation of the cGAS-STING-CCL5 pathway in mesenchymal stromal cells. Cell Death Dis. 2020;11(5):326.
13. Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov. 2020;10(1):26-39.
14. Zhu L, Li Y, Xie X, Zhou X, Gu M, Jie Z, et al. TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis. Nat Cell Biol. 2019;21(12):1604-14.
15. Qing T, Yamin Z, Guijie W, Yan J, Zhongyang S. STAT6 silencing induces hepatocellular carcinoma-derived cell apoptosis and growth inhibition by decreasing the RANKL expression. Biomed Pharmacother. 2017;92:1-6.
16. Yang H, Wang H, Ren J, Chen Q, Chen ZJ. cGAS is essential for cellular senescence. Proc Natl Acad Sci USA. 2017;114(23):E4612-E20.
17. Gu Z, Li Y, Yang X, Yu M, Chen Z, Zhao C, et al. Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer. J Hematol Oncol. 2018;11(1):115.
18. Thomsen MK, Skouboe MK, Boularan C, Vernejoul F, Lioux T, Leknes SL, et al. The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma. Oncogene. 2020;39(8):1652-64.
19. Wang J, Ba G, Han Y-Q, Ming S-L, Wang M-D, Fu P-F, et al. Cyclic GMP-AMP synthase is essential for cytosolic double-stranded DNA and fowl adenovirus serotype 4 triggered innate immune responses in chickens. Int J Biol Macromol. 2020;146:497-507.
20. Li R, Yang Y, An Y, Zhou Y, Liu Y, Yu Q, et al. Genetic polymorphisms in DNA double-strand break repair genes XRCC5, XRCC6 and susceptibility to hepatocellular carcinoma. Carcinogenesis. 2011;32(4):530-6.
21. Marozin S, Altomonte J, Stadler F, Thasler WE, Schmid RM, Ebert O. Inhibition of the IFN-β Response in Hepatocellular Carcinoma by Alternative Spliced Isoform of IFN Regulatory Factor-3. Mol Ther. 2008;16(11):1789-97.
22. Wang Z, Lin H, Hua F, Hu Z-w. Repairing DNA damage by XRCC6/KU70 reverses TLR4-deficiency-worsened HCC development via restoring senescence and autophagic flux. Autophagy. 2013;9(6):925-7.
23. Lin W, Zhao Z, Ni Z, Zhao Y, Du W, Chen S. IFI16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasomes. Cell Prolif. 2017;50(6).
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-50.
25. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1-6.
26. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649-58.
27. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
28. Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322-33.
29. Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227.
30. Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956-D63.
31. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer research. 2017;77(21):e108-e10.
32. Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.
33. Wurmbach E, Chen Y-b, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45(4):938-47.
34. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med. 2009;15(3-4):85-94.
35. Roessler S, Jia H-L, Budhu A, Forgues M, Ye Q-H, Lee J-S, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer research. 2010;70(24):10202-12.
36. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, et al. Gene expression patterns in human liver cancers. Mol Biol Cell. 2002;13(6):1929-39.
37. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678-83.
38. Ahn J, Xia T, Konno H, Konno K, Ruiz P, Barber GN. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun. 2014;5:5166.
39. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108-12.
40. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-14.
41. Al-Eitan LN, Rababa’h DM, Alghamdi MA, Khasawneh RH. Genetic association of gene polymorphisms with breast cancer among Jordanian women. Onco Targets Ther. 2019;12:7923-8.
42. Liu ZH, Wang N, Wang FQ, Dong Q, Ding J. High expression of XRCC5 is associated with metastasis through Wnt signaling pathway and predicts poor prognosis in patients with hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2019;23(18):7835-47.
43. Jiao S, Guan J, Chen M, Wang W, Li C, Wang Y, et al. Targeting IRF3 as a YAP agonist therapy against gastric cancer. J Exp Med. 2018;215(2):699-718.
44. Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med.
25

2018;24(8):1143-50.

45. Lazzari E, Korczeniewska J, Ni Gabhann J, Smith S, Barnes BJ, Jefferies CA. TRIM21 (TRIM21) differentially regulates the stability of interferon regulatory factor 5 (IRF5) isoforms. PLoS ONE. 2014;9(8):e103609.

46. Zhang L, Mo J, Swanson KV, Wen H, Petrucelli A, Gregory SM, et al. NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. Immunity. 2014;40(3):329-41.

47. Engen JR, Wales TE, Hochrein JM, Meyn MA, Banu Ozkan S, Bahar I, et al. Structure and dynamic regulation of Src-family kinases. Cellular and molecular life sciences : CMLS. 2008;65(19):3058-73.

48. Fukumoto Y, Morii M, Miura T, Kubota S, Ishibashi K, Honda T, et al. Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint. J Biol Chem. 2014;289(18):12313-29.

49. al-Ramadi BK, Zhang H, Bothwell AL. Cell-cycle arrest and apoptosis hypersusceptibility as a consequence of Lck deficiency in nontransformed T lymphocytes. Proc Natl Acad Sci USA. 1998;95(21):12498-503.

50. Lavin MF, Scott S, Gueven N, Kozlov S, Peng C, Chen P. Functional consequences of sequence alterations in the ATM gene. DNA Repair (Amst). 2004;3(8-9):1197-205.

51. Kouhkan F, Mobarza N, Soufi-Zomorrod M, Keramati F, Hosseini Rad SMA, Fathi-Roudsari M, et al. MicroRNA-129-1 acts as a tumour suppressor and induces cell cycle arrest of GBM cancer cells through targeting IGF2BP3 and MAPK1. J Med Genet. 2016;53(1):24-33.

52. Montero JC, Seoane S, Ocaña A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumours. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(17):5546-52.

53. Pizarro JG, Folch J, de la Torre AV, Junyent F, Verdaguer E, Jordan J, et al. ATM is involved in cell-cycle control through the regulation of retinoblastoma protein phosphorylation. J Cell Biochem. 2010;110(1):210-8.

54. Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142-9.

55. Woo S-R, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MYK, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830-42.

56. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782-95.

57. Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55-61.

58. Lin P, Guo Y-N, Shi L, Li X-J, Yang H, He Y, et al. Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer. Aging (Albany NY). 2019;11(2):480-500.

59. Luo X, Li H, Ma L, Zhou J, Guo X, Woo S-L, et al. Expression of STING Is Increased in Liver Tissues From Patients With NAPLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice. Gastroenterology. 2018;155(6).
60. Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A, et al. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol. 2012;189(9):4258-65.
61. Huang Y-H, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, et al. Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2016;536(7616):359.
62. Liang D, Xiao-Feng H, Guan-Jun D, Er-Ling H, Sheng C, Ting-Ting W, et al. Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal. Biochim Biophys Acta. 2015;1852(11):2494-503.

**Figure Legends**

**Figure 1** Transcriptional expression of 12 cGAS-STING pathway members in 20 different types of cancer (Oncomine database). Differences in transcriptional expression were compared using Student's t-test. The cutoff criteria were as follows: p=0.01, fold change=1.5, gene rank=10%, and data type of mRNA.

**Figure 2** mRNA expression of different cGAS-STING pathway members in HCC samples and adjacent normal liver samples (UALCAN). The mRNA expression of XRCC5, IRF3, TRIM21, STAT6, DDX41, TBK1, XRCC6, TREX1, PRKDC, and TMEM173 was found to be upregulated in HCC tissues versus normal tissues (A–C, E, G–L). The transcriptional levels of IFI16 and NLRC3 did not show significant differences (D, F). ***p<0.001.

**Figure 3** Representative immunohistochemistry images of different cGAS-STING pathway members in HCC tissues and normal liver tissues (Human Protein Atlas). STAT6, TBK1, and TREX1 proteins were not expressed in normal liver tissues, whereas they exhibited medium or high expression in HCC samples (D, F, H). In addition, low or medium protein expression of XRCC5, IRF3, TRIM21, DDX41, XRCC6, and cGAS was observed in normal liver tissues; high expression of these proteins was noted in HCC tissues (A–C, E, G, I).
Figure 4 Relationship between the mRNA expression of different cGAS-STING pathway members and individual cancer stages in patients with HCC. The mRNA expression of 10 cGAS-STING pathway members was strongly related with the cancer stages of individual patients. Patients who were in more advanced stages tended to express higher mRNA levels of cGAS-STING pathway members. The highest mRNA expression of DDX41 was found in stage 4 (G), while the highest mRNA expression of XRCC5, IRF3, TRIM21, STAT6, TBK1, XRCC6, TREX1, and PRKDC was found in stage 3 (A–C, E, H–K). The highest mRNA expression of TMEM173 was found in stage 1 (L). However, the mRNA expression of IFI16 and NLRC3 did not show a correlation with tumor grades in patients with liver cancer (D, F). *p<0.05, **p<0.01, ***p<0.001.

Figure 5 Association of mRNA expression of different cGAS-STING pathway members with tumor grades in patients with HCC. The mRNA expression of 10 cGAS-STING pathway members was significantly related with tumor grades; as the tumor grade increased, the mRNA expression of cGAS-STING pathway members tended to increase in parallel. The highest mRNA expression of XRCC5, IRF3, DDX41, TBK1, XRCC6, and PRKDC was found in grade 4 tumors (A, B, G–I, K), while the highest mRNA expression of TRIM21, STAT6, and TMEM173 was found in grade 3 tumors (C, E, L). However, the highest mRNA expression of IFI16 and TREX1 was found in grade 1 or 2; as the tumor grade increased, the mRNA expression of IFI16 and TREX1 tended to decrease (D, J). NLRC3 mRNA expression did not show a correlation with tumor grades in patients with liver cancer (F). *p<0.05, **p<0.01, ***p<0.001.

Figure 6 Prognostic value of mRNA expression of different cGAS-STING pathway members in patients with HCC (Kaplan–Meier
Higher mRNA expression of XRCC5, XRCC6, and PRKDC was significantly associated with shorter OS in patients with liver cancer (A, I, K). In contrast, higher mRNA expression of IFI16, STAT6, NLRC3, and TMEM173 was significantly related with favorable OS in patients with liver cancer (D–F, L). However, IRF3, TRIM21, DDX41, TBK1, and TREX1 mRNA expression did not show a correlation with prognosis in patients with HCC (B, C, G, H, J).

**Figure 7** Correlation between differentially expressed cGAS-STING pathway members and immune cell infiltration (TIMER). Relationship between the abundance of immune cells and expression of (A) XRCC5, (B) IRF3, (C) TRIM21, (D) IFI16, (E) STAT6, (F) NLRC3, (G) DDX41, (H) TBK1, (I) XRCC6, (J) TREX1, and (K) PRKDC in HCC.

**Table 1** Significant changes in the transcription levels of cGAS-STING pathway members between HCC and normal liver tissues (Oncomine).

**Table 2** The kinase target networks of cGAS-STING pathway members in HCC (LinkedOmics).

**Supplementary Table 1** Correlation analysis among XRCC5, IRF3, TRIM21, and IFI16 and related genes and markers of immune cells in TIMER.

**Supplementary Table 2** Correlation analysis among STAT6, NLRC3, DDX41, and TBK1 and related genes and markers of immune cells in TIMER.

**Supplementary Table 3** Correlation analysis among XRCC6, TREX1, and PRKDC, and related genes and markers of immune cells in TIMER.
| Analysis Type by Cancer | Cancer vs. Normal | Cancer vs. Normal | Cancer vs. Normal | Cancer vs. Normal | Cancer vs. Normal | Cancer vs. Normal | Cancer vs. Normal | Cancer vs. Normal | Cancer vs. Normal |
|-------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                         | XRCC5             | IRF3              | TRIM21            | IFI16             | STAT6             | NLRC3             | DDX41             | TBK1              | XRCC6             | TREX1             | PRKDC             | TMEM173            |
| Bladder Cancer          |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Brain and CNS Cancer    |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Breast Cancer           |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Cervical Cancer         |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Colorectal Cancer       |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Esophageal Cancer       |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Gastric Cancer          |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Head and Neck Cancer    |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Kidney Cancer           |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Leukemia                |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Liver Cancer            |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Lung Cancer             |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Lymphoma                |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Melanoma                |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Myeloma                 |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Other Cancer            |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Ovarian Cancer          |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Pancreatic Cancer       |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Prostate Cancer         |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Sarcoma                 |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |

**Significant Unique Analyses**

|                        | 56 | 36 | 2 | 20 | 2 | 92 | 27 | 21 | 17 | 7 | 14 | 27 | 2 | 10 | 12 | 26 | 9 | 20 | 10 | 103 | 7 | 31 | 10 |
|------------------------|----|----|---|----|---|----|----|----|----|---|----|----|---|----|----|----|---|----|----|------|---|----|----|
| **Total Unique Analyses** | 358 | 358 | 347 | 361 | 354 | 190 | 295 | 267 | 342 | 298 | 361 | 361 | 358 | 358 | 347 | 361 | 354 | 190 | 295 | 267 | 342 | 298 | 361 | 361 |
Table 1: Significant changes in the transcription levels of cGAS-STING pathway members between HCC and normal liver tissues (Oncomine).

| Types of HCC VS. Liver | Fold Change | P value  | t-test | Ref                   |
|------------------------|-------------|----------|--------|-----------------------|
| TRIM21                 | 1.607       | 4.78E-04 | 3.847  | Wurmbach Liver[34]    |
| IFI16                  | 3.474       | 4.23E-14 | 10.895 | Mas Liver[35]         |
|                        | 4.715       | 1.91E-16 | 15.089 | Mas Liver[35]         |
|                        | 3.649       | 1.02E-06 | 7.012  | Wurmbach Liver[34]    |
|                        | 2.250       | 4.06E-04 | 3.861  | Wurmbach Liver[34]    |
| NLRC3                  | 2.197       | 1.35E-05 | 5.560  | Wurmbach Liver[34]    |
| DDX41                  | 2.012       | 7.60E-08 | 6.619  | Roessler Liver[36]    |
|                        | 1.719       | 5.25E-07 | 6.074  | Wurmbach Liver[34]    |
|                        | 1.701       | 2.95E-41 | 15.050 | Roessler Liver 2[36]  |
| XRCC6                  | 1.828       | 1.47E-70 | 21.477 | Roessler Liver 2[36]  |
| TREX1                  | 1.552       | 0.002    | 3.172  | Wurmbach Liver[34]    |
| PRKDC                  | 2.792       | 4.91E-72 | 23.447 | Roessler Liver 2[36]  |
|                        | 3.011       | 9.67E-09 | 7.102  | Wurmbach Liver[34]    |
|                        | 1.651       | 8.50E-15 | 8.386  | Chen Liver[37]        |
|                        | 2.439       | 6.57E-08 | 7.031  | Roessler Liver[36]    |
| Kinase target network | Description | Leading EdgeNum | P value |
|-----------------------|-------------|----------------|---------|
| XRCC5                 | Polo like kinase 1 | 51 | 0 |
| Kinase_ATR            | ATR serine/threonine kinase | 32 | 0 |
| IRF3                  | Dual specificity tyrosine phosphorylation regulated kinase 1A | 7 | 0.004 |
| Kinase_EGFR           | Epidermal growth factor receptor | 17 | 0.008 |
| TRIM21                | LYN proto-oncogene, Src family tyrosine kinase | 22 | 0 |
| Kinase_LCK            | LCK proto-oncogene, Src family tyrosine kinase | 31 | 0 |
| IFI16                 | Spleen associated tyrosine kinase | 21 | 0 |
| Kinase_LCK            | LCK proto-oncogene, Src family tyrosine kinase | 25 | 0 |
| STAT6                 | ATR serine/threonine kinase | 31 | 0 |
| Kinase_ATR            | Polo like kinase 1 | 32 | 0 |
| Kinase_DYRK1A         | Dual specificity tyrosine phosphorylation regulated kinase 1A | 6 | 0.011 |
| Gene   | Kinase   | Description                                      | Score | P-value |
|--------|----------|--------------------------------------------------|-------|---------|
| TBK1   | ATM      | ATM serine/threonine kinase                      | 56    | 0       |
|        | DAPK1    | death associated protein kinase 1                | 6     | 0       |
| XRCC6  | AURKB    | aurora kinase B                                  | 41    | 0       |
|        | PLK1     | polo like kinase 1                               | 34    | 0       |
| TREX1  | ATM      | ATM serine/threonine kinase                      | 69    | 0       |
|        | CDK2     | cyclin dependent kinase 2                        | 124   | 0       |
| PRKDC  | ATM      | ATM serine/threonine kinase                      | 63    | 0       |
|        | CDK1     | cyclin dependent kinase 1                        | 125   | 0       |
| TMEM173| BUB1     | BUB1 mitotic checkpoint serine/threonine kinase  | 4     | 0.029   |
|        | HCK      | HCK proto-oncogene, Src family tyrosine kinase   | 10    | 0.028   |
Supplementary Table 1 Correlation analysis among XRCC5, IRF3, TRIM21, and IFI16 and related genes and markers of immune cells in TIMER.

| Description          | Gene Markers | XRCC5 |    | IRF3 |    | TRIM21 |    | IFI16 |    |
|----------------------|--------------|-------|---|------|---|--------|---|-------|---|
|                      |              | None  |    | None  |    | None   |    | None  |    |
|                      |              | Cor   |   | Cor   |   | Cor    |   | Cor   |   |
|                      |              | P     |   | P     |   | P      |   | P     |   |
| CD8+ T cell          | CD8A         | 0.179 | ***| 0.253 | ***| 0.202  | ***| 0.231 | ***| 0.330  | ***| 0.279  | ***| 0.579  | ***| 0.458  | ***|
|                      | CD8B         | 0.118 | * | 0.185 | ***| 0.290  | ***| 0.321 | ***| 0.256  | ***| 0.204  | ***| 0.475  | ***| 0.340  | ***|
| T cell (general)     | CD3D         | 0.111 | * | 0.178 | ***| 0.413  | ***| 0.458 | ***| 0.350  | ***| 0.328  | ***| 0.515  | ***| 0.388  | ***|
|                      | CD3E         | 0.146 | **| 0.241 | ***| 0.267  | ***| 0.329 | ***| 0.372  | ***| 0.334  | ***| 0.642  | ***| 0.517  | ***|
|                      | CD2          | 0.131 | * | 0.220 | ***| 0.320  | ***| 0.377 | ***| 0.388  | ***| 0.358  | ***| 0.610  | ***| 0.485  | ***|
| B cell               | CD19         | 0.165 | **| 0.192 | ***| 0.307  | ***| 0.325 | ***| 0.270  | ***| 0.213  | ***| 0.437  | ***| 0.328  | ***|
|                      | CD79A        | 0.066 | 0.205| 0.130 | * | 0.266  | ***| 0.293 | ***| 0.241  | ***| 0.161  | ** | 0.535  | ***| 0.402  | ***|
| Monocyte             | CD86         | 0.322 | ***| 0.430 | ***| 0.254  | ***| 0.301 | ***| 0.451  | ***| 0.426  | ***| 0.692  | ***| 0.588  | ***|
| TAM                  | CSF1R        | 0.277 | ***| 0.381 | ***| 0.181  | ***| 0.217 | ***| 0.439  | ***| 0.403  | ***| 0.682  | ***| 0.568  | ***|
|                      | CCL2         | 0.186 | ***| 0.255 | ***| 0.109  | * | 0.126 | *  | 0.383  | ***| 0.341  | ***| 0.635  | ***| 0.523  | ***|
|                      | CD68         | 0.246 | ***| 0.309 | ***| 0.157  | * | 0.172 | ** | 0.328  | ***| 0.281  | ***| 0.484  | ***| 0.349  | ***|
|                      | IL10         | 0.264 | ***| 0.339 | ***| 0.127  | * | 0.151 | ** | 0.313  | ***| 0.248  | ***| 0.551  | ***| 0.425  | ***|
| M1 Macrophage        | NOS2         | 0.150 | ** | 0.155 | ***| -0.132 | * | -0.122 | *  | 0.151  | ** | 0.134  | *  | 0.241  | ***| 0.232  | ***|
|                | IRF5  | PTGS2 | CD163 | VSIG4 | M2 CD163*** | MS4A4A | CD163*** | VSIG4*** | M2 CD163*** | MS4A4A*** |
|----------------|-------|-------|--------|-------|-------------|--------|----------|----------|-------------|-----------|
| Neutrophils    |       |       |        |       |             |        |          |          |             |           |
|                |       |       |        |       |             |        |          |          |             |           |
|                | CEACAM8 | 0.084 | 0.106  | 0.095 | 0.079       | 0.033  | 0.523    | 0.051    | 0.341       | 0.016     |
|                |       |       |        |       |             |        |          |          |             |           |
|                | ITGAM | 0.273 | 0.319  | 0.248 | 0.373       | 0.273  | 0.467    | 0.460    | 0.569       | 0.492     |
|                |       |       |        |       |             |        |          |          |             |           |
|                | CCR7  | 0.134 | 0.215  | 0.143 | 0.180       | 0.312  | 0.247    | 0.593    | 0.451       |           |
| Natural killer cell |    |       |        |       |             |        |          |          |             |           |
| KIR2DL1        | 0.052 | 0.317 | 0.026  | 0.627 | 0.068       | 0.189  | 0.094    | 0.081    | 0.008       | 0.875     |
|                |       |       |        |       |             |        |          |          |             |           |
| KIR2DL3        | 0.160 | 0.188 | 0.126  | 0.140 | 0.252       | 0.214  | 0.290    | 0.246    |             |           |
|                |       |       |        |       |             |        |          |          |             |           |
| KIR2DL4        | 0.157 | 0.175 | 0.194  | 0.207 | 0.315       | 0.291  | 0.376    | 0.334    |             |           |
| KIR3DL1        | 0.132 | 0.146 | 0.048  | 0.356 | 0.074       | 0.170  | 0.117    | 0.074    | 0.170       | 0.207     |
|                |       |       |        |       |             |        |          |          |             |           |
| KIR3DL2        | 0.121 | 0.157 | 0.128  | 0.141 | 0.126       | 0.086  | 0.110   | 0.280    | 0.204       |           |
| KIR3DL3        | 0.075 | 0.148 | 0.076  | 0.159 | 0.012       | 0.821  | 0.012    | 0.852    | 0.024       | 0.646     |
|                |       |       |        |       |             |        |          |          |             |           |
| KIR2DS4        | 0.176 | 0.185 | 0.018  | 0.734 | 0.031       | 0.566  | 0.051    | 0.326    | 0.061       | 0.257     |
|                |       |       |        |       |             |        |          |          |             |           |
| Dendritic cell | HLA-DPB1 | 0.232 | 0.309  | 0.218 | 0.249       | 0.447  | 0.416    | 0.709    | 0.614       |           |
|                |       |       |        |       |             |        |          |          |             |           |
|                | HLA-DQB1 | 0.153 | 0.219  | 0.242 | 0.264       | 0.364  | 0.334    | 0.576    | 0.456       |           |
|                |       |       |        |       |             |        |          |          |             |           |
|                | HLA-DRA | 0.266 | 0.346  | 0.148 | 0.170       | 0.513  | 0.489    | 0.708    | 0.613       |           |

*p < 0.05, **p < 0.01, ***p < 0.001.
| Pathway  | Gene   | Th1   | Th2   | Tfh   | Treg   |
|---------|--------|-------|-------|-------|--------|
| HLA-DPA1 | 0.275  | ***   | 0.361 | ***   | 0.130  | *      | 0.159  | **    | 0.487  | ***   | 0.466  | ***   | 0.719  | ***   | 0.629  | ***   |
| CD1C    | 0.258  | ***   | 0.320 | ***   | 0.158 | **    | 0.170  | **    | 0.282  | ***   | 0.240  | ***   | 0.523  | ***   | 0.416  | ***   |
| NRP1    | 0.532  | ***   | 0.552 | ***   | 0.053 | 0.312 | 0.049  | 0.362 | 0.243  | ***   | 0.221  | ***   | 0.457  | ***   | 0.433  | ***   |
| ITGAX   | 0.294  | ***   | 0.377 | ***   | 0.284 | ***   | 0.333  | **    | 0.421  | ***   | 0.398  | ***   | 0.619  | ***   | 0.518  | ***   |
| Th1     | TBX21  | 0.141 | **    | 0.208 | ***   | 0.137 | **    | 0.170 | **    | 0.302  | ***   | 0.240  | ***   | 0.496  | ***   | 0.366  | ***   |
| STAT4   | 0.228  | ***   | 0.270 | ***   | 0.256 | ***   | 0.248  | ***   | 0.395  | ***   | 0.372  | ***   | 0.506  | ***   | 0.451  | ***   |
| STAT1   | 0.488  | ***   | 0.526 | ***   | 0.277 | ***   | 0.279  | ***   | 0.576  | ***   | 0.552  | ***   | 0.561  | ***   | 0.535  | ***   |
| IFNG    | 0.140  | **    | 0.191 | ***   | 0.268 | ***   | 0.297  | ***   | 0.303  | ***   | 0.276  | ***   | 0.399  | ***   | 0.302  | ***   |
| TNF     | 0.258  | ***   | 0.346 | ***   | 0.271 | ***   | 0.315  | ***   | 0.422  | ***   | 0.391  | ***   | 0.543  | ***   | 0.439  | ***   |
| Th2     | GATA3  | 0.223 | ***   | 0.326 | ***   | 0.190 | ***   | 0.225 | ***   | 0.349  | ***   | 0.298  | ***   | 0.627  | ***   | 0.532  | ***   |
| STAT6   | 0.380  | ***   | 0.365 | ***   | 0.024 | 0.645 | 0.012  | 0.821 | 0.312  | ***   | 0.289  | ***   | 0.239  | ***   | 0.261  | ***   |
| STAT5A  | 0.352  | ***   | 0.389 | ***   | 0.309 | ***   | 0.315  | ***   | 0.324  | ***   | 0.295  | ***   | 0.526  | ***   | 0.454  | ***   |
| IL13    | 0.074  | 0.153 | 0.062 | 0.252 | 0.156 | **    | 0.150  | **    | 0.168  | **    | 0.144  | **    | 0.134  | **    | 0.113  | *     |
| Tfh     | BCL6   | 0.361 | ***   | 0.353 | ***   | 0.046 | 0.380 | 0.066 | 0.220 | 0.142  | **    | 0.152  | **    | 0.194  | ***   | 0.246  | ***   |
| IL21    | 0.078  | 0.132 | 0.116 | *     | 0.099 | 0.056 | 0.125  | *     | 0.150  | **    | 0.142  | **    | 0.168  | **    | 0.136  | *     |
| Th17    | STAT3  | 0.321 | ***   | 0.344 | ***   | -0.016 | 0.759 | -0.01 | 0.856 | 0.443  | ***   | 0.420  | ***   | 0.519  | ***   | 0.487  | ***   |
| IL17A   | 0.094  | 0.070 | 0.108 | *     | -0.005 | 0.921 | 0.014 | 0.793 | 0.042 | 0.421  | 0.048 | 0.374 | 0.137 | **    | 0.146 | **     |
| Treg    | FOXP3  | 0.242 | ***   | 0.274 | ***   | -0.046 | 0.375 | -0.016 | 0.773 | 0.378  | ***   | 0.362  | ***   | 0.330  | ***   | 0.270  | ***   |
| CCR8    | 0.386  | ***   | 0.458 | ***   | 0.134 | **    | 0.147  | **    | 0.428  | ***   | 0.400  | ***   | 0.579  | ***   | 0.519  | ***   |
| STAT5B  | 0.500  | ***   | 0.490 | ***   | -0.063 | 0.227 | -0.063 | 0.244 | 0.251  | ***   | 0.296  | ***   | 0.128  | *     | 0.243  | ***   |
| TGFB1   | 0.319  | ***   | 0.398 | ***   | 0.362 | ***   | 0.392  | ***   | 0.284  | ***   | 0.225  | ***   | 0.539  | ***   | 0.422  | ***   |
| T cell exhaustion | PDCD1 | 0.183  | ***   | 0.245  | ***   | 0.402  | ***   | 0.442  | ***   | 0.300  | ***   | 0.252  | ***   | 0.497  | ***   | 0.380  | ***   |
|------------------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|-------|-------|-------|
|                  | CTLA4 | 0.155  | **    | 0.218  | ***   | 0.410  | ***   | 0.454  | ***   | 0.299  | ***   | 0.267  | ***   | 0.496  | ***   | 0.375  | ***   |
|                  | LAG3  | 0.149  | **    | 0.177  | ***   | 0.355  | ***   | 0.361  | ***   | 0.272  | ***   | 0.238  | ***   | 0.303  | ***   | 0.212  | ***   |
|                  | HAVCR2| 0.303  | ***   | 0.411  | ***   | 0.283  | ***   | 0.338  | ***   | 0.437  | ***   | 0.409  | ***   | 0.703  | ***   | 0.606  | ***   |
|                  | GZMB  | 0.107  | *     | 0.130  | *     | 0.184  | ***   | 0.215  | ***   | 0.132  | *     | 0.052  | 0.334  | 0.417  | ***   | 0.305  | ***   |
Supplementary Table 2 Correlation analysis among STAT6, NLRC3, DDX41, and TBK1 and related genes and markers of immune cells in TIMER.

| Description          | Gene Markers | STAT6          |       |       | NLRC3          |       |       | DDX41          |       |       | TBK1          |       |       |
|----------------------|--------------|----------------|-------|-------|----------------|-------|-------|----------------|-------|-------|----------------|-------|-------|
|                      |              | Cor | P   | Cor | P   | Cor | P   | Cor | P   | Cor | P   | Cor | P   | Cor | P   | Cor | P   | Cor | P   | Cor | P   |
| CD8+ T cell          | CD8A         | 0.131 | *  | 0.151 | ** | 0.737 | *** | 0.675 | *** | 0.045 | 0.388 | 0.100 | 0.064 | 0.197 | *** | 0.211 | *** |
|                      | CD8B         | 0.002 | 0.966 | 0.012 | 0.829 | 0.612 | *** | 0.528 | *** | 0.027 | 0.609 | 0.074 | 0.172 | 0.068 | 0.191 | 0.075 | 0.162 |
| T cell (general)     | CD3D         | -0.006 | 0.906 | 0.004 | 0.946 | 0.627 | *** | 0.539 | *** | 0.032 | 0.538 | 0.093 | 0.085 | 0.096 | 0.066 | 0.107 | *    |
|                      | CD3E         | 0.103 | *  | 0.126 | *  | 0.797 | *** | 0.732 | *** | 0.002 | 0.971 | 0.067 | 0.214 | 0.166 | **  | 0.188 | *** |
|                      | CD2          | 0.085 | 0.101 | 0.111 | *  | 0.783 | *** | 0.721 | *** | -0.004 | 0.943 | 0.057 | 0.293 | 0.154 | **  | 0.179 | *** |
| B cell               | CD19         | 0.093 | 0.074 | 0.077 | 0.151 | 0.528 | *** | 0.427 | *** | 0.072 | 0.164 | 0.092 | 0.088 | 0.174 | *** | 0.162 | **   |
|                      | CD79A        | 0.025 | 0.626 | 0.023 | 0.670 | 0.642 | *** | 0.526 | *** | -0.039 | 0.450 | 0.003 | 0.953 | 0.071 | 0.175 | 0.064 | 0.235 |
| Monocyte             | CD86         | 0.163 | *  | 0.190 | *** | 0.726 | *** | 0.637 | *** | 0.146 | **  | 0.227 | *** | 0.350 | *** | 0.410 | *** |
|                      | CSF1R        | 0.205 | *** | 0.236 | *** | 0.699 | *** | 0.595 | *** | 0.137 | **  | 0.216 | *** | 0.303 | *** | 0.358 | *** |
| TAM                  | CCL2         | 0.165 | **  | 0.188 | *** | 0.617 | *** | 0.487 | *** | 0.047 | 0.371 | 0.129 | *   | 0.268 | *** | 0.314 | *** |
|                      | CD68         | 0.146 | **  | 0.156 | *  | 0.494 | *** | 0.358 | *** | 0.079 | 0.127 | 0.128 | *   | 0.289 | *** | 0.314 | *** |
|                      | IL10         | 0.135 | **  | 0.138 | *  | 0.584 | *** | 0.451 | *** | 0.078 | 0.136 | 0.122 | *   | 0.311 | *** | 0.340 | *** |
| M1 Macrophage        | NOS2         | 0.216 | *** | 0.216 | *** | 0.235 | *** | 0.216 | *** | 0.093 | 0.075 | 0.104 | 0.054 | 0.243 | *** | 0.244 | *** |
|                      | IRF5         | 0.366 | *** | 0.362 | *** | 0.355 | *** | 0.395 | *** | 0.417 | *** | 0.410 | *** | 0.463 | *** | 0.469 | *** |
|          | PTGS2 | M2 Macrophage | CD163 | VSIG4 | MS4A4A | Neutrophils | CEACAM8 | ITGAM | CCR7 | Natural killer cell | KIR2DL1 | KIR2DL3 | KIR2DL4 | KIR3DL1 | KIR3DL2 | KIR3DL3 | KIR2DS4 | KIR2DS5 | Dendritic cell | HLA-DPB1 | HLA-DQB1 | HLA-DRA | HLA-DPA1 |
|----------|-------|--------------|-------|-------|--------|-------------|---------|-------|------|---------------------|---------|---------|---------|---------|---------|---------|---------|---------|----------------|---------|---------|---------|---------|
|          | 0.199 | 0.204 ***    | 0.194 | 0.199 | 0.194 | −0.045      | 0.259   | 0.120 | 0.074 | 0.182               | 0.074   | 0.182   | 0.127   | 0.222   | 0.064   | 0.083   | 0.210   | 0.163   | 0.056   | 0.213   | 0.206   |
|          | 0.233 | 0.225 ***    | 0.231 | 0.238 | 0.222 | 0.388       | 0.284   | 0.121 | 0.153 | 0.177               | 0.153   | 0.177   | 0.132   | 0.225   | 0.082   | 0.109   | 0.218   | 0.183   | 0.279   | 0.236   | 0.225   |
|          | 0.623 | 0.627 ***    | 0.565 | 0.627 | 0.317   | −0.047      | 0.529   | 0.725 | 0.418 | 0.364               | 0.418   | 0.364   | 0.373   | 0.317   | 0.126   | 0.426   | 0.276   | 0.728   | 0.219   | 0.729   | 0.748   |
|          | 0.506 | 0.512 ***    | 0.436 | 0.502 | 0.311   | 0.204       | 0.448   | 0.622 | 0.153 | 0.333               | 0.333   | 0.333   | 0.328   | 0.311   | 0.347   | 0.137   | 0.319   | 0.640   | 0.592   | 0.640   | 0.667   |
|          | 0.003 | 0.053        | 0.111 | 0.060 | −0.085  | −0.046      | 0.297   | 0.425 | 0.210 | 0.144               | 0.144   | 0.144   | 0.129   | 0.013   | 0.070   | 0.059   | 0.063   | 0.124   | 0.103   | 0.118   | 0.111   |
|          | 0.949 | 0.307        | 0.176 | 0.251 | 0.104   | −0.029      | 0.356   | 0.104 | 0.053 | 0.187               | 0.187   | 0.187   | 0.148   | 0.807   | 0.182   | 0.257   | 0.225   | 0.184   | 0.160   | 0.182   | 0.179   |
|          | 0.083 | 0.097        | 0.322 | 0.133 | 0.04    | 0.720       | 0.418   | 0.459 | 0.312 | 0.176               | 0.176   | 0.176   | 0.171   | 0.146   | 0.089   | 0.031   | 0.057   | 0.205   | 0.109   | 0.301   | 0.299   |
|          | 0.125 | 0.071        | 0.385 | 0.363 | 0.998   | 0.099       | 0.418   | 0.184 | 0.031 | 0.175               | 0.175   | 0.175   | 0.171   | 0.157   | 0.089   | 0.040   | 0.104   | 0.229   | 0.109   | 0.339   | 0.340   |
|          | 0.367 | 0.359        | 0.437 | 0.412 | 0.807   | 0.089       | 0.476   | 0.198 | 0.570 | 0.174               | 0.174   | 0.174   | 0.175   | 0.157   | 0.101   | 0.853   |                   |               |                    |                    |
| Gene    | Value 1 | Value 2 | Value 3 | Value 4 | Value 5 | Value 6 | Value 7 | Value 8 | Value 9 | Value 10 |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|----------|
| CD1C    | 0.144   | **      | 0.153   | **      | 0.658   | ***     | 0.580   | ***     | −0.002  | 0.970    | 0.315    | 0.208    | ***     | 0.226   | ***     |
| NRP1    | 0.458   | ***     | −0.003  | 0.957   | 0.517   | ***     | 0.506   | ***     | 0.135   | **       | 0.165    | 0.534    | ***     | 0.546   | ***     |
| ITGAX   | 0.218   | ***     | 0.245   | ***     | 0.683   | ***     | 0.588   | ***     | 0.172   | ***      | 0.235    | ***     | 0.392   | ***     | 0.442   | ***     |
| Th1     | TBX21   | 0.160   | **      | 0.174   | **      | 0.727   | ***     | 0.655   | ***     | −0.068  | 0.194    | −0.03    | 0.572    | 0.166   | **      | 0.175   |
| STAT4   | 0.159   | **      | 0.173   | **      | 0.565   | ***     | 0.522   | ***     | 0.012   | 0.816    | 0.044    | 0.411    | 0.242   | ***     | 0.260   |
| STAT1   | 0.326   | ***     | 0.324   | ***     | 0.600   | ***     | 0.587   | ***     | 0.194   | ***      | 0.210    | ***     | 0.514   | ***     | 0.518   |
| IFNG    | 0.029   | 0.583   | 0.044   | 0.410   | 0.514   | ***     | 0.450   | ***     | 0.126   | *        | 0.170    | **       | 0.171   | ***     | 0.191   |
| TNF     | 0.163   | **      | 0.183   | ***     | 0.666   | ***     | 0.577   | ***     | 0.091   | *        | 0.150    | **       | 0.316   | ***     | 0.349   |
| Th2     | GATA3   | 0.142   | **      | 0.178   | ***     | 0.769   | ***     | 0.704   | ***     | 0.036   | 0.491    | 0.093    | 0.083    | 0.256   | ***     | 0.304   |
| STAT6   | 1.000   | ***     | −1      | ***     | 0.326   | ***     | 0.360   | ***     | 0.143   | **       | 0.120    | *        | 0.542   | ***     | 0.518   |
| STAT5A  | 0.330   | ***     | 0.346   | ***     | 0.573   | ***     | 0.531   | ***     | 0.202   | ***      | 0.220    | ***     | 0.394   | ***     | 0.411   |
| IL13    | −0.054  | 0.303   | −0.084  | 0.118   | 0.179   | ***     | 0.163   | **      | 0.106   | *        | 0.077    | 0.155    | 0.108   | *       | 0.105   | 0.052   |
| Th17    | BCL6    | 0.374   | ***     | 0.368   | ***     | 0.199   | ***     | 0.239   | ***     | 0.118   | *        | 0.111    | *        | 0.427   | ***     | 0.431   |
| IL21    | 0.046   | 0.378   | 0.065   | 0.232   | 0.235   | ***     | 0.212   | ***     | 0.013   | 0.801    | 0.037    | 0.495    | 0.140   | **       | 0.154   |
| Treg    | FOXP3   | 0.168   | **      | 0.155   | **      | 0.470   | ***     | 0.425   | ***     | 0.083   | 0.110    | 0.135    | *        | 0.358   | ***     | 0.370   |
| CCR8    | 0.276   | ***     | 0.294   | ***     | 0.663   | ***     | 0.612   | ***     | 0.144   | **       | 0.181    | ***     | 0.512   | ***     | 0.551   |
| STAT5B  | 0.496   | ***     | 0.486   | ***     | 0.309   | ***     | 0.456   | ***     | 0.244   | ***      | 0.217    | ***     | 0.648   | ***     | 0.660   |
| TGFB1   | 0.140   | **      | 0.152   | **      | 0.563   | ***     | 0.455   | ***     | 0.176   | ***      | 0.253    | ***     | 0.250   | ***     | 0.274   |
| T cell  | PDCD1   | 0.068   | 0.194   | 0.063   | 0.240   | 0.607   | ***     | 0.518   | ***     | 0.108   | *        | 0.171    | **       | 0.155   | **      | 0.146   |
| exhaustion |         |        |          |          |          |         |         |          |          |          |          |          |         |          |          |
|       | CTLA4  | LAG3   | HAVCR2 | GZMB   |
|-------|--------|--------|--------|--------|
|       | 0.034  | -0.004 | 0.140  | 0.079  |
|       | 0.514  | 0.931  | **     | 0.129  |
|       | 0.045  | -0.004 | 0.169  | 0.058  |
|       | 0.407  | 0.935  | **     | 0.282  |
|       | 0.587  | 0.456  | **     | 0.497  |
|       | ***    | ***    | ***    | ***    |
|       | 0.495  | 0.407  | 0.601  | 0.394  |
|       | ***    | ***    | ***    | ***    |
|       | 0.084  | 0.033  | 0.151  | 0.021  |
|       | 0.108  | 0.530  | 0.228  | 0.689  |
|       | 0.147  | 0.046  | 0.333  | 0.066  |
|       | **     | 0.389  | ***    | 0.222  |
|       | 0.161  | 0.083  | ***    | 0.069  |
|       | **     | 0.109  | ***    | 0.184  |
|       | **     | 0.079  | ***    | 0.048  |
|       | **     | 0.141  | ***    | 0.374  |
### Supplementary Table 3 Correlation analysis among XRCC6, TREX1, and PRKDC, and related genes and markers of immune cells in TIMER.

| Description          | Gene Markers | XRCC6 |  |  | TREX1 |  |  | PRKDC |  |  |
|----------------------|--------------|-------|---|---|-------|---|---|-------|---|---|
|                      |              | Cor   | P  | Cor | P     | Cor | P  | Cor   | P  | Cor   | P  | Cor | P  |
| **CD8+ T cell**      | CD8A         | 0.132 | *  | 0.216 | *** | 0.154 | ** | 0.076 | 0.157 | 0.166 | ** | 0.184 | *** |
|                      | CD8B         | 0.128 | *  | 0.216 | *** | 0.157 | ** | 0.085 | 0.113 | 0.083 | 0.109 | 0.097 | 0.071 |
| **T cell (general)** | CD3D         | 0.153 | ** | 0.243 | *** | 0.116 | *  | 0.036 | 0.507 | 0.139 | ** | 0.159 | **  |
|                      | CD3E         | 0.122 | *  | 0.235 | *** | 0.112 | *  | 0.006 | 0.915 | 0.183 | *** | 0.215 | *** |
|                      | CD2          | 0.124 | *  | 0.233 | *** | 0.123 | *  | 0.027 | 0.617 | 0.172 | *** | 0.208 | *** |
| **B cell**           | CD19         | 0.205 | *** | 0.257 | *** | 0.113 | *  | 0.035 | 0.512 | 0.205 | *** | 0.199 | *** |
|                      | CD79A        | 0.098 | 0.060 | 0.199 | *** | 0.067 | 0.201 | −0.041 | 0.453 | 0.117 | *  | 0.127 | *  |
| **Monocyte**         | CD86         | 0.322 | *** | 0.454 | *** | 0.177 | *** | 0.100 | 0.063 | 0.357 | *** | 0.417 | *** |
|                      | CSF1R        | 0.265 | *** | 0.388 | *** | 0.227 | *** | 0.150 | 0.301 | 0.353 | *** | 0.353 | *** |
| **TAM**              | CCL2         | 0.125 | *  | 0.199 | *** | 0.253 | *** | 0.195 | 0.182 | 0.189 | *** | 0.189 | *** |
|                      | CD68         | 0.269 | *** | 0.357 | *** | 0.101 | 0.052 | 0.019 | 0.725 | 0.344 | *** | 0.378 | *** |
|                      | IL10         | 0.211 | *** | 0.299 | *** | 0.171 | *** | 0.092 | 0.088 | 0.289 | *** | 0.313 | *** |
| **M1 Macrophage**    | NOS2         | 0.035 | 0.500 | 0.044 | 0.420 | 0.141 | ** | 0.125 | 0.020 | 0.165 | ** | 0.165 | ** |
|                      | IRF5         | 0.371 | *** | 0.375 | *** | 0.142 | ** | 0.130 | 0.015 | 0.433 | *** | 0.417 | *** |
|                      | PTGS2        | 0.161 | *  | 0.247 | *** | 0.160 | ** | 0.093 | 0.086 | 0.284 | *** | 0.317 | *** |
| **M2 Macrophage**    | CD163        | 0.181 | *** | 0.271 | *** | 0.167 | ** | 0.093 | 0.083 | 0.290 | *** | 0.337 | *** |
|                      | VSIG4        | 0.173 | *** | 0.268 | *** | 0.185 | *** | 0.120 | 0.026 | 0.244 | *** | 0.280 | *** |
|                      | MS4A4A       | 0.196 | *** | 0.307 | *** | 0.170 | ** | 0.099 | 0.065 | 0.271 | *** | 0.324 | *** |
| **Neutrophils**      | CEACAM8      | 0.083 | 0.112 | 0.095 | 0.078 | −0.073 | 0.161 | −0.087 | 0.108 | 0.066 | 0.205 | 0.055 | 0.312 |
|                      | ITGAM        | 0.282 | *** | 0.345 | *** | 0.222 | *** | 0.185 | 0.370 | 0.406 | *** | 0.406 | *** |
|                      | CCR7         | 0.072 | 0.166 | 0.156 | ** | 0.087 | 0.095 | −0.022 | 0.679 | 0.181 | *** | 0.201 | *** |
| **Natural killer cell** | KIR2DL1    | −0.058 | 0.266 | −0.087 | 0.108 | 0.055 | 0.289 | 0.015 | 0.780 | 0.074 | 0.155 | 0.052 | 0.335 |
|                      | KIR2DL3     | 0.070 | 0.176 | 0.117 | *  | 0.202 | *** | 0.151 | ** | 0.091 | 0.080 | 0.109 | *  |
| Cell Type | Gene   | Effect Size | Confidence Interval | p-value |
|----------|--------|-------------|---------------------|---------|
| Dendritic cell | HLA-DPB1 | 0.226 | *** 0.323 *** | 0.205 *** 0.117 * 0.222 *** 0.242 *** |
| Dendritic cell | HLA-DQB1 | 0.138 | ** 0.211 *** 0.133 * 0.044 0.415 0.157 ** 0.162 ** |
| Dendritic cell | HLA-DRA | 0.230 | *** 0.329 *** 0.210 *** 0.131 * 0.290 *** 0.327 *** |
| Dendritic cell | HLA-DPA1 | 0.211 | *** 0.305 *** 0.176 *** 0.088 0.104 0.272 *** 0.306 *** |
| Th1 | CD1C | 0.181 | *** 0.236 *** 0.029 0.583 −0.058 0.282 0.240 *** 0.239 *** |
| Th1 | NRP1 | 0.421 | *** 0.433 *** 0.100 0.055 0.062 0.253 0.500 *** 0.506 *** |
| Th1 | ITGAX | 0.270 | *** 0.373 *** 0.131 * 0.049 0.360 0.409 *** 0.458 *** |
| Th2 | TBX21 | 0.041 | 0.428 0.119 * 0.128 * 0.028 0.608 0.162 ** 0.184 *** |
| Th2 | STAT4 | 0.098 | 0.059 0.138 * 0.083 0.111 0.042 0.438 0.197 *** 0.209 *** |
| Th2 | STAT1 | 0.384 | *** 0.433 *** 0.137 ** 0.090 0.094 0.450 *** 0.468 *** |
| Th2 | IFNG | 0.148 | ** 0.222 *** 0.139 ** 0.084 0.122 0.142 ** 0.167 ** |
| Th2 | TNF | 0.221 | *** 0.329 *** 0.144 ** 0.052 0.334 0.329 *** 0.382 *** |
| Tfh | GATA3 | 0.128 | * 0.235 *** 0.122 * 0.023 0.674 0.232 *** 0.285 *** |
| Tfh | STAT6 | 0.257 | *** 0.247 *** 0.159 ** 0.132 * 0.390 *** 0.374 *** |
| Tfh | STAT5A | 0.350 | *** 0.392 *** 0.262 *** 0.230 *** 0.369 *** 0.385 *** |
| T cell exhaustion | IL13 | −0.035 0.506 −0.039 0.467 0.166 ** 0.149 ** 0.014 0.789 0.005 0.928 *** |
| Tfh | BCL6 | 0.289 | *** 0.278 *** 0.014 0.781 0.017 0.749 0.340 *** 0.332 *** |
| Tfh | IL21 | 0.073 | 0.163 0.104 0.053 0.150 ** 0.126 * 0.081 0.118 0.096 0.075 *** |
| Th17 | STAT3 | 0.214 | *** 0.243 *** 0.094 0.070 0.051 0.348 0.417 *** 0.431 *** |
| Th17 | IL17A | 0.039 | 0.452 0.042 0.442 −0.08 0.122 −0.069 0.204 0.108 * 0.109 * |
| Treg | FOXP3 | 0.084 | 0.105 0.119 * 0.199 *** 0.171 ** 0.258 *** 0.276 *** |
| Treg | CCR8 | 0.271 | *** 0.353 *** 0.060 0.250 −0.008 0.886 0.488 *** 0.543 *** |
| Treg | STAT5B | 0.356 | *** 0.337 *** 0.029 0.582 0.048 0.373 0.533 *** 0.540 *** |
| Treg | TGFB1 | 0.325 | *** 0.426 *** 0.066 0.204 −0.025 0.646 0.306 *** 0.338 *** |
| T cell exhaustion | PDCD1 | 0.226 | *** 0.318 *** 0.129 * 0.038 0.479 0.201 *** 0.209 *** |
| T cell exhaustion | CTLA4 | 0.212 | *** 0.294 *** 0.063 0.228 −0.013 0.808 0.191 *** 0.214 *** |
| T cell exhaustion | LAG3 | 0.139 | ** 0.181 *** 0.157 ** 0.114 * 0.102 * 0.101 0.062 *** |
|     | HAVCR2 |     |     |     | GZMB |     |     |     |     |     |     |
|-----|--------|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|
|     | 0.291  |     |     | *** | 0.424| *** | 0.173| *** | 0.100| 0.065| 0.344 |
|     |        |     |     |     | 0.065| 0.211| 0.104| 0.053| 0.188| ...  | 0.117 |
|     |        |     |     |     |      |      |      |      |      |      |      |
|     |        |     |     |     | 0.415| 0.054| 0.296| 0.044| 0.444| 0.047| 0.407 |
EDITORIAL CERTIFICATE

This document certifies that the manuscript below was edited for correct English language usage, grammar, punctuation and spelling by qualified native English speaking editors at Charlesworth Author Services.

Paper Title:
Identification of Prognostic Biomarkers and Correlations with Immune Infiltrates among cGAS-STING in Hepatocellular Carcinoma

Author:
Qi Zhenhua

Date certificate issued:
September 09, 2020

cwauthors.com